Drew Fabrizio Kendrick Williamson, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Mutational Analysis | 1 | 2022 | 4188 | 0.440 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 6172 | 0.420 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 2213 | 0.350 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5221 | 0.280 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13096 | 0.180 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2021 | 104 | 0.180 |
Why?
|
| Privacy | 1 | 2021 | 239 | 0.170 |
Why?
|
| Game Theory | 1 | 2019 | 25 | 0.170 |
Why?
|
| Synthetic Biology | 1 | 2021 | 179 | 0.170 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 532 | 0.160 |
Why?
|
| Humerus | 1 | 2020 | 266 | 0.160 |
Why?
|
| Kidney Neoplasms | 3 | 2022 | 4245 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 720 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 1036 | 0.130 |
Why?
|
| Medicine | 1 | 2023 | 946 | 0.120 |
Why?
|
| Language | 1 | 2024 | 1471 | 0.120 |
Why?
|
| Neurology | 1 | 2022 | 764 | 0.120 |
Why?
|
| Workflow | 3 | 2024 | 847 | 0.120 |
Why?
|
| Acetabulum | 1 | 2017 | 525 | 0.110 |
Why?
|
| Osteoarthritis, Hip | 1 | 2017 | 412 | 0.110 |
Why?
|
| Genomics | 3 | 2022 | 5722 | 0.100 |
Why?
|
| Histological Techniques | 2 | 2022 | 198 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2021 | 3328 | 0.100 |
Why?
|
| Tibia | 1 | 2016 | 1077 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2016 | 1579 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 14726 | 0.090 |
Why?
|
| Cadaver | 3 | 2020 | 1337 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2021 | 3130 | 0.080 |
Why?
|
| Femur | 1 | 2015 | 1297 | 0.080 |
Why?
|
| Radiology | 1 | 2022 | 2099 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 2281 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2021 | 6196 | 0.080 |
Why?
|
| Glioma | 1 | 2022 | 3401 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5319 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2021 | 13036 | 0.070 |
Why?
|
| Knee Joint | 1 | 2015 | 1680 | 0.070 |
Why?
|
| Algorithms | 2 | 2022 | 13885 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2019 | 4440 | 0.060 |
Why?
|
| Humans | 20 | 2024 | 744220 | 0.050 |
Why?
|
| Bioreactors | 1 | 2022 | 236 | 0.050 |
Why?
|
| Information Theory | 1 | 2021 | 51 | 0.050 |
Why?
|
| Mutation | 2 | 2022 | 29784 | 0.050 |
Why?
|
| Diaphyses | 1 | 2020 | 65 | 0.040 |
Why?
|
| Histocytochemistry | 1 | 2021 | 719 | 0.040 |
Why?
|
| Epiphyses | 1 | 2020 | 189 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 108 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 843 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11493 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 1655 | 0.040 |
Why?
|
| Microscopy | 1 | 2021 | 903 | 0.030 |
Why?
|
| Femur Neck | 1 | 2017 | 309 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 491 | 0.030 |
Why?
|
| Femur Head | 1 | 2017 | 301 | 0.030 |
Why?
|
| Rotation | 1 | 2016 | 523 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2015 | 211 | 0.030 |
Why?
|
| Sex Factors | 2 | 2020 | 10396 | 0.030 |
Why?
|
| Femoracetabular Impingement | 1 | 2017 | 189 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 21672 | 0.030 |
Why?
|
| Women's Health | 1 | 2022 | 2034 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 2914 | 0.030 |
Why?
|
| Anthropometry | 1 | 2017 | 1350 | 0.030 |
Why?
|
| Prognosis | 2 | 2022 | 29050 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 20817 | 0.020 |
Why?
|
| Age Factors | 2 | 2020 | 18367 | 0.020 |
Why?
|
| Observer Variation | 1 | 2017 | 2593 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2022 | 2265 | 0.020 |
Why?
|
| Female | 8 | 2022 | 380197 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 4841 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2022 | 4220 | 0.020 |
Why?
|
| Computational Biology | 1 | 2021 | 3523 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4982 | 0.020 |
Why?
|
| Software | 1 | 2023 | 4442 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2726 | 0.020 |
Why?
|
| Middle Aged | 5 | 2021 | 213367 | 0.020 |
Why?
|
| Adult | 5 | 2021 | 214035 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 3508 | 0.020 |
Why?
|
| Male | 6 | 2021 | 350027 | 0.020 |
Why?
|
| Aged | 4 | 2021 | 163253 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2022 | 4463 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2021 | 3747 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16687 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 9849 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7179 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 19907 | 0.010 |
Why?
|
| Risk Factors | 2 | 2017 | 72280 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 15538 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 13668 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2021 | 40559 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 57768 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 25043 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 77426 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 56436 | 0.010 |
Why?
|